REVIEW

Refinement of a mouse cardiovascular model: Development, application and dissemination [version 1; peer review: 2 approved, 1 approved with reservations]

Kirk A. Taylor, Michael Emerson

Platelet Biology Group, National Heart and Lung Institute, Imperial College London, London, SW7 2AZ, UK

V1 First published: 15 May 2018, 7:593
<https://doi.org/10.12688/f1000research.14456.1>
 Latest published: 15 May 2018, 7:593
<https://doi.org/10.12688/f1000research.14456.1>

Abstract

European and UK legislation requires all animal procedures to be conducted with consideration to reduction, refinement and replacement. In this review, 3Rs developments are discussed in the field of platelet biology and thromboembolism. Platelet research requires the use of animal models, and mice are widely used in the field. When working *in vitro*, conventional light transmission techniques have been scaled down allowing reduction in animal numbers. *In vivo*, vascular injury models are widely used and work is ongoing to develop *ex vivo* approaches that use fewer animals. Thromboembolic mortality models, which inflict considerable pain and suffering, have also been used widely. A published and characterised refinement of this mortality model allows real-time monitoring of radiolabelled platelets under general anaesthesia and reduces both the severity level and the numbers of mice used in a typical experiment. This technique is more sensitive than the mortality approach and has opened up new avenues of research, which would not have been feasible by using death as an end-point. To drive uptake of real-time monitoring, a more simplistic approach has been developed involving micro-sampling and cell counting. Thromboembolic mortality models should therefore be considered obsolete due to the emergence of 3Rs models with improved scientific outcomes and that can be implemented relatively easily.

Keywords

endothelium, mortality, mouse, pharmacology, platelet, reduction refinement, thrombosis

Open Peer Review

Approval Status

	1	2	3
version 1			
15 May 2018	view	view	view

1. **Sarah Jones**, Manchester Metropolitan University, Manchester, UK
2. **David J. Grieve**, Queen's University Belfast, Belfast, UK
3. **Alan G.S. Harper** , Keele University, Keele, UK

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the NC3Rs gateway.

Corresponding author: Michael Emerson (m.emerson@imperial.ac.uk)

Author roles: **Taylor KA:** Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Emerson M:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by research grants from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (grant numbers: G0600382/1; G0900732/1; NC/M000079/1).

Copyright: © 2018 Taylor KA and Emerson M. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Taylor KA and Emerson M. **Refinement of a mouse cardiovascular model: Development, application and dissemination [version 1; peer review: 2 approved, 1 approved with reservations]** F1000Research 2018, 7:593 <https://doi.org/10.12688/f1000research.14456.1>

First published: 15 May 2018, 7:593 <https://doi.org/10.12688/f1000research.14456.1>

Research highlights

Scientific benefits:

- Acquisition of pharmacodynamics dose-responses increases sensitivity
- Platelet function is assessed directly

3Rs benefits:

- Procedures are conducted at a lower severity level avoiding pain and suffering
- Animal numbers are reduced by 85%

Practical benefits:

- Simplistic alternative micro-sampling approaches are available that require only standard laboratory equipment and minimal training

Current applications:

- Investigating cardiovascular risk associated with exposure to airborne pollution and HIV/antiretroviral therapy

Future applications:

- Broadly within the fields of anti-thrombotic therapy and platelet physiology/pharmacology
- Potential for further reduction in the field by developing flow cytometric approaches for multiple analyses of diluted micro-samples

Cardiovascular diseases and platelets

Cardiovascular diseases including myocardial infarction (MI) and stroke are the major cause of death in Western society. Cardiovascular risk is heightened by the unavoidable risk factor of age, but is also driven by avoidable, or potentially avoidable, factors such as smoking, poor diet and airborne pollution¹. Cardiovascular disease is also increasingly important to clinicians and scientists in other fields. For example, cardiovascular events are the major cause of death in people living with HIV who are virally suppressed by antiretroviral therapy².

When investigating mechanisms of cardiovascular disease, platelets are of obvious interest. Platelets are circulating blood elements with central roles in haemostasis and thrombosis and are a major therapeutic target in the treatment of arterial thrombotic events such as MI. Aspirin and clopidogrel inhibit platelet activation and are widely prescribed in patients following MI, although their efficacy remains suboptimal and new therapeutic approaches are required.

When activated, platelets undergo a series of signalling processes involving calcium release and the expression of activation markers, including P-selectin, on the extracellular surface. Platelets also release a range of inflammatory mediators from intracellular granules, including chemokines such as PF4 (Platelet Factor 4) and CCL5 (chemokine (C-C motif) ligand 5). Platelets therefore generate a range of signals that drive processes such as adhesion, aggregation and inflammation. Human platelets are easily isolated from blood and their function may be assessed through a range of established assays. The gold-standard functional assay remains light transmission aggregometry, which measures

increases of light transmission through initially opaque platelet suspensions as platelets aggregate³.

In vitro and *ex vivo* analysis of platelet function

Platelets are anucleate and it is not possible to alter protein expression using traditional *in vitro* strategies, such as siRNA knockdown. Therefore, it is often necessary to employ mouse models where protein expression of the precursor cell, the megakaryocyte, can be altered. A significant reduction achievement concerning *in vitro* mouse platelet aggregometry has been the development of 96-well plate light transmission approaches⁴, which use much smaller plasma volumes than conventional cuvette approaches. By reducing the standard plasma volume from 450 to 90 μ l, a reduction in mouse use of 80% is possible when switching to a 96-well format. In addition, running multiple samples in parallel in a 96-well plate, rather than consecutive cuvette analyses, can reduce sample variability and thus reduce numbers of animals required per experiment.

Flow cytometry is widely used in biomedical research and with an increasing number of available antibodies and markers that permit diverse analysis in very small samples of cells and fluids, this approach can dramatically increase the number of experimental parameters per experiment. Platelet researchers routinely monitor high affinity integrin $\alpha_{IIb}\beta_3$, alpha and dense granule release as markers of platelet activation alongside assays to determine changes of Ca^{2+} signalling and aggregation⁵⁻⁸. Emergent flow cytometers, such as the BD Accuri C6, enable agonists to be added during sample acquisition, allowing for simultaneous kinetic evaluation of platelet activation⁸. A major advantage of this technology is that data can be obtained with diluted samples (i.e. 1:200), raising the possibility that micro-sampling could replace alternative blood collection techniques, such as retro-orbital sampling and cardiac puncture. Ongoing work in our laboratory is evaluating the potential of using flow cytometry to perform ratiometric analysis of agonist-evoked calcium signalling, platelet aggregation and protein studies using human samples. If successful, these techniques could be applied to mouse studies and reduce the overall number of animals required.

Reporting of numbers of animals used per experiment in the literature is highly variable and it is often not possible to determine whether the same animal has been used in multiple assays. Taking these limitations into account, we predict that measurement of platelet activation markers, aggregation response and calcium response to three platelet agonists using conventional assays would require 13 mice per experimental replicate. However, development of flow cytometric approaches discussed here could reduce this number by over 90%.

Need for animal models

The involvement of multiple cell types and tissues in the etiology of cardiovascular diseases creates a strong necessity for animal studies, and more than 63,000 animal procedures involving mice were reported in the Cardiovascular, Blood and Lymphatic field by the UK Home Office in 2016 (<https://www.gov.uk/government/statistics/statistics-of-scientific-procedures-on-living-animals-great-britain-2016>).

Within the field of thrombosis and platelets, vascular injury models involving endothelial damage via chemical, laser or mechanical trauma and subsequent thrombus formation are widely used⁹. Although the technique is conducted terminally under general anaesthesia, the number of thrombi that can be recorded per animal is limited, since, for example, both carotid arteries cannot be ligated. In addition, the high variance of the data outputs mean that relatively high numbers of animals are required to statistically power studies. Efforts are currently underway to develop an *ex vivo* carotid artery model involving luminal cannulation of excised artery sections: <https://www.nc3rs.org.uk/reducing-animal-use-thrombosis-research-ex-vivo-injury-model>. In due course, it is hoped that this model will reduce mouse use by at least 50% since both carotid arteries can be used.

The vascular endothelium releases mediators such as nitric oxide (NO) and prostacyclin, which inhibit platelet function and are central to both haemostasis and the development of platelet-driven cardiovascular events¹⁰⁻¹². Vascular injury models have proven to be problematic when used to assess the impact of endothelial mediators in platelet-driven thrombosis. In the NO field, ablation of endothelial NO synthase (eNOS) was shown to result in no phenotype^{13,14}, an anti-thrombotic phenotype^{15,16} or a pro-thrombotic phenotype¹⁷ by different groups using similar experimental approaches. Assessment of the role of endothelial mediators requires, rather than a vascular injury approach, a model in which platelets circulate freely in the context of a functional vascular endothelium, which can be manipulated pharmacologically or genetically¹⁸.

Animal models: Need for refinement

The need to model platelet function and thrombosis *in vivo* has led to the development of vascular injury models, which are conducted under general anaesthesia, but also to the use of models of thromboembolic mortality, which are conducted in conscious animals and, as the name suggests, use mortality as an end-point¹⁹. Thromboembolic mortality models allow the assessment of platelet aggregation *in vivo* against the backdrop of a functional vascular endothelium. Mortality models involve the intravenous injection of thrombogenic agents such as collagen or thrombin with death or hind limb paralysis as an end-point. To quote from a 2003 publication²⁰: “*Pulmonary embolism was induced in male Swiss-Webster mice by intravenous tail injection of a mixture of collagen and epinephrine. Doses were selected that resulted in death or at least 15 minutes of hind-limb paralysis in approximately 90% of control mice*”. The effects of genetic modification or drug action are measured by their ability to significantly change the proportions of mice killed or paralysed. This model has been used relatively recently to assess the roles of novel intracellular signalling pathways in platelets²¹, endogenous compounds²², platelet receptor antagonists²³, free radical scavengers²⁴, dietary compounds²⁵, endogenous nitric oxide¹⁰ and a novel aspirin derivative²⁶ on thromboembolic mortality.

Induction of thromboembolism in mice undoubtedly inflicts considerable pain and suffering. Following injection, the mice adopt a hunched posture, become immobile and breathing becomes

laboured¹⁹. The mice remain in this state until they die or are assessed, by their inability to use their hind-limbs, to be paralysed. The rationale for conducting the procedure in conscious mice is that under anaesthetic, mortality is more difficult to induce¹⁹ (presumably shock contributes to death and blood pressure is lower under anaesthesia) and paralysis cannot easily be determined. In addition to the severe impact upon the animals, this technique requires large numbers of subjects and studies have been published involving 20 or 40 animals per experimental group^{10,27}, so that the total number in a publication can run into the hundreds.

Refined model development

We have developed refined models for the assessment of platelet thromboembolism using monitoring of radiolabelled platelets in anaesthetised mice^{28,29}. Our technique avoids the use of death as an end-point and instead measures the thromboembolic response in real-time by tracking radiolabelled platelets *via* externally placed scintillation probes²⁸. To achieve this, mice are terminally anaesthetised and bled by cardiac puncture, platelets are radiolabelled with a gamma emitter and then infused into a second terminally anaesthetised mouse. Thus, a model is created in which radiolabelled platelets circulate freely against the background of a fully functional vascular endothelium, and so retaining a key feature that has been used historically to justify the use of thromboembolic mortality models. The same range of thrombogenic substances that can be used to induce mortality, when given at lower doses, induce reversible and dose-dependent increases in platelet counts in a probe suspended over the pulmonary vascular bed. Thus, the whole time course of the platelet thromboembolic response may be recorded and quantified in a number of ways, including peak response and area under the curve²⁸. We were able to validate our model with the anti-platelet drug aspirin as a means of assessing its potential clinical relevance²⁸.

Reduction

Despite the fact that real-time monitoring requires animals both for acquisition of platelets and monitoring, our approach allows not only refinement of procedures to a lower severity level, but has also reduced the numbers of animals required in a typical experiment. The extent of reduction is best exemplified when looking at work demonstrating the role of endogenous NO in inhibiting platelet activation *in vivo*. This was first demonstrated in mice in 1998 when administration of a NO synthase inhibitor was shown to increase thromboembolic mortality in mice¹⁰. This paper required the use of 200 mice to demonstrate the antithrombotic activity of endogenous NO and additional studies (including *in vivo* studies in other species) to link mortality studies with a platelet-mediated effect. A comparable study using refined real-time platelet monitoring involved only 30 mice with all procedures performed under general anaesthesia (classified as non-recovery severity level under current Home Office legislation). Thus the refined model led to an 85% reduction in mouse use in a typical experiment¹⁸.

Scientific application of refined model

Real-time platelet monitoring produces dynamic and quantifiable read-outs and provides dose-dependent platelet accumulation

responses. This contrasts with mortality studies which simply measure the occurrence, or lack of, an event. The refined model should therefore provide greater sensitivity since we are able to detect shifts in pharmacodynamic dose-responses, reflecting either enhanced or reduced platelet activation. We suggest that recent work in the field of cardiovascular risk in the context of airborne pollution demonstrates this^{30,31}. It has been known for many years that exposure to pollution leads to increased cardiovascular morbidity and mortality and, in particular, exposure to particulate pollution increases myocardial infarction, a platelet-driven cardiovascular event³². Due to their physicochemical properties, combustion-derived nanoparticles such as diesel exhaust particles (DEP) have been strongly implicated in driving cardiovascular risk³³. DEP have been shown to induce inflammation³⁴ and due to their nanoparticulate nature are hypothesised to translocate across the pulmonary epithelial barrier into the blood³⁵, which would bring them into direct contact with circulating platelets. Having shown that DEP can interact physically with platelets and induce their aggregation in *in vitro* human studies³⁰, it was necessary to proceed to *in vivo* studies to translate this finding to a more relevant whole organism setting. It was shown that both introduction of DEP to circulating blood to mimic translocation³⁰ and tracheal instillation of DEP to mimic inhalation³¹ resulted in a significantly enhanced platelet thromboembolic response at doses of DEP that reflected human exposure levels. These studies contributed to the now more widely accepted thinking that DEP exposure may enhance cardiovascular risk in the human population and provided a potential mechanism. We suggest that this type of work, which highlights relatively subtle events that require sensitive models, would not have been possible in mortality models, certainly not at doses of DEP that were relevant to human exposure levels.

Dissemination and uptake

3Rs benefits of animals arise not from their development, which creates potential, but from their subsequent employment in studies where non-refined models would have been used in the absence of refined alternatives. Examples from our own group have been discussed above and there are other outcomes in the fields of nanotoxicology³⁶, nutritional biochemistry³⁷ and calcium signalling³⁸. We have also collaborated with other groups in the fields of cyclooxygenase pharmacology¹², integrin linked kinase⁸ and sulforaphane (an isothiocyanate with potential antithrombotic activity; unpublished study, authors: Gillespie, Holloway, Becker, Rauzi, Vital, Shreveport, Taylor, Stokes, Emerson and Gavins).

The ultimate aim of 3Rs research is broad uptake of emerging 3Rs technologies by the scientific community and a consequential reduction in the use of non-refined procedures. Quantification of continued use of thromboembolic mortality models is difficult since their use is often obscured through lack of inclusion in abstracts and use of vague terminology. PubMed searches of [thromboembolism + mouse] and [thrombosis + mortality + mouse] and [platelet + mortality + mouse], followed by a manual search to identify publications revealed more than 50 papers where thromboembolic mortality was used in 2013. A review of these papers found that all used mortality and/or paralysis as end-points,

the duration of the experiments varied from 5 minutes to 96 hours, and experimental groups varied from 10 to 30 mice, with 10 to 360 mice used in total in each paper. Similar numbers of papers appear in the 5 years preceding 2013.

More recently, in 2016³⁹, we sampled 9 peer review articles using models of thromboembolic mortality and found between 3 and 40 animals per experimental group, with some studies not reporting animal use, the duration of the period in which animals were observed following induction of thromboembolism varied from 5 min to 5 days. Anaesthesia of any sort was only used in one study. Unfortunately, thromboembolic mortality models are therefore still used despite the availability of an alternative refined model. Potential reasons for continued use of thromboembolic mortality models are: Lack of awareness of alternatives, animal welfare not a primary consideration, inability to work with radioisotopes, lack of expertise and preference for collaboration rather than establishment of new technologies

Increasing awareness of the 3Rs and refined models is an ongoing endeavour and we continue to work collaboratively. In addition, we set out to develop refined methods to study platelet thromboembolism *in vivo* that could be more widely adopted since they could be conducted with minimal training, non-specialised equipment and at low cost. We have now developed a model that allows thromboembolism to be assessed by measuring the fall in circulating platelets that occurs during thromboembolism in blood microsamples³⁹. Microsamples are taken from the tail vein of anaesthetised mice and repeated sampling allows for counts to be measured before and during the thromboembolic response in an individual animal. This technique allows thromboembolism to be assessed without the need for specialised equipment and without radioisotopes.

Conclusions

In conclusion, platelet function can now be assessed *in vitro* and *in vivo* using 3Rs approaches that reduce the severity level and also the numbers of animals used in procedures. Thromboembolic mortality approaches should now be considered obsolete, since even where the gold-standard real-time monitoring technique cannot be employed, more simplistic assays can be used without the need for radioactive material or complex procedures.

Data availability

No data are associated with this article.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by research grants from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (grant numbers: G0600382/1; G0900732/1; NC/M000079/1).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Mills NL, Donaldson K, Hadoke PW, *et al.*: **Adverse cardiovascular effects of air pollution.** *Nat Clin Pract Cardiovasc Med.* 2009; **6**(1): 36–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Durand M, Sheehy O, Baril JG, *et al.*: **Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.** *J Acquir Immune Defic Syndr.* 2011; **57**(3): 245–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Born GV: **Aggregation of blood platelets by adenosine diphosphate and its reversal.** *Nature.* 1962; **194**: 927–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Armstrong PC, Dhanji AR, Truss NJ, *et al.*: **Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.** *Thromb Haemost.* 2009; **102**(4): 772–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Taylor KA, Wright JR, Vial C, *et al.*: **Amplification of human platelet activation by surface pannexin-1 channels.** *J Thromb Haemost.* 2014; **12**(6): 987–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Gupta S, Cherpokova D, Spindler M, *et al.*: **GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice.** *Blood.* 2018; **131**(10): 1106–1110.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Taylor KA, Wilson DGS, Harper MT, *et al.*: **Extracellular chloride is required for efficient platelet aggregation.** *Platelets.* 2018; **29**(1): 79–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Jones CI, Tucker KL, Sasikumar P, *et al.*: **Integrin-linked kinase regulates the rate of platelet activation and is essential for the formation of stable thrombi.** *J Thromb Haemost.* 2014; **12**(8): 1342–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Bodary PF, Eitzman DT: **Animal models of thrombosis.** *Curr Opin Hematol.* 2009; **16**(5): 342–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Emerson M, Momi S, Paul W, *et al.*: **Endogenous nitric oxide acts as a natural antithrombotic agent *in vivo* by inhibiting platelet aggregation in the pulmonary vasculature.** *Thromb Haemost.* 1999; **81**(6): 961–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Moore C, Tymvios C, Emerson M: **Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase.** *Thromb Haemost.* 2010; **104**(2): 342–349.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Armstrong PC, Kirkby NS, Zain ZN, *et al.*: **Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.** *PLoS One.* 2011; **6**(5): e20062.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Ozuyaman B, Godecke A, Kusters S, *et al.*: **Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation.** *Thromb Haemost.* 2005; **93**(6): 1161–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Dayal S, Wilson KM, Leo L, *et al.*: **Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia.** *Blood.* 2006; **108**(7): 2237–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Iafra MD, Vitseva O, Tanriverdi K, *et al.*: **Compensatory mechanisms influence hemostasis in setting of eNOS deficiency.** *Am J Physiol Heart Circ Physiol.* 2005; **288**(4): H1627–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Marjanovic JA, Li Z, Stojanovic A, *et al.*: **Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation.** *J Biol Chem.* 2005; **280**(45): 37430–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Heeringa P, van Goor H, Itoh-Lindstrom Y, *et al.*: **Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis.** *Am J Pathol.* 2000; **156**(3): 879–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Emerson M: **Refinement, reduction and replacement approaches to *in vivo* cardiovascular research.** *Br J Pharmacol.* 2010; **161**(4): 749–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. DiMinno G, Silver MJ: **Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents *in vivo*. Potentiation of antithrombotic activity by ethyl alcohol.** *J Pharmacol Exp Ther.* 1983; **225**(1): 57–60.
[PubMed Abstract](#)
20. Matys T, Kucharewicz I, Pawlak R, *et al.*: **Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.** *J Cardiovasc Pharmacol.* 2003; **42**(6): 710–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Jin YR, Hwang KA, Cho MR, *et al.*: **Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative.** *Vascul Pharmacol.* 2004; **41**(1): 35–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Konstantinides S, Schafer K, Neels JG, *et al.*: **Inhibition of endogenous leptin protects mice from arterial and venous thrombosis.** *Arterioscler Thromb Vasc Biol.* 2004; **24**(11): 2196–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Katada J, Takiguchi Y, Muramatsu M, *et al.*: **The *in vitro* and *in vivo* pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.** *Thromb Res.* 1997; **88**(1): 27–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hsiao G, Shen MY, Lin KH, *et al.*: **Inhibitory activity of kinetin on free radical formation of activated platelets *in vitro* and on thrombus formation *in vivo*.** *Eur J Pharmacol.* 2003; **465**(3): 281–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Kang WS, Lim IH, Yuk DY, *et al.*: **Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate.** *Thromb Res.* 1999; **96**(3): 229–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Momi S, Emerson M, Paul W, *et al.*: **Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin.** *Eur J Pharmacol.* 2000; **397**(1): 177–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Park J, Lee B, Choi H, *et al.*: **Antithrombotic activity of protocatechuic and shikimic acids from functional plant *Pinus densiflora* Sieb. et Zucc needles.** *J Nat Med.* 2016; **70**(3): 492–501.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Tymvios C, Jones S, Moore C, *et al.*: **Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse.** *Thromb Haemost.* 2008; **99**(2): 435–440.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Holbrook L, Moore C, Sanz-Rosa D, *et al.*: **A NOD/SCID mouse model for the assessment of human platelet aggregation *in vivo*.** *J Thromb Haemost.* 2012; **10**(3): 490–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Solomon A, Smyth E, Mittha N, *et al.*: **Induction of platelet aggregation after a direct physical interaction with diesel exhaust particles.** *J Thromb Haemost.* 2013; **11**(2): 325–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Smyth E, Solomon A, Birrell MA, *et al.*: **Influence of inflammation and nitric oxide upon platelet aggregation following deposition of diesel exhaust particles in the airways.** *Br J Pharmacol.* 2017; **174**(13): 2130–2139.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Peters A, Dockery DW, Muller JE, *et al.*: **Increased particulate air pollution and the triggering of myocardial infarction.** *Circulation.* 2001; **103**(23): 2810–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Donaldson K, Tran L, Jimenez LA, *et al.*: **Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure.** *Part Fibre Toxicol.* 2005; **2**: 10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Bérubé K, Balharry D, Sexton K, *et al.*: **Combustion-derived nanoparticles: mechanisms of pulmonary toxicity.** *Clin Exp Pharmacol Physiol.* 2007; **34**(10): 1044–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Kreyling WG, Semmler-Behnke M, Seitz J, *et al.*: **Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs.** *Inhal Toxicol.* 2009; **21** Suppl 1: 55–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Smyth E, Solomon A, Vydyanath A, *et al.*: **Induction and enhancement of platelet aggregation *in vitro* and *in vivo* by model polystyrene nanoparticles.** *Nanotoxicology.* 2015; **9**(3): 356–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Apostoli GL, Solomon A, Smallwood MJ, *et al.*: **Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation *in vitro* and *in vivo*.** *J Thromb Haemost.* 2014; **12**(11): 1880–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Jones S, Solomon A, Sanz-Rosa D, *et al.*: **The plasma membrane calcium ATPase modulates calcium homeostasis, intracellular signaling events and function in platelets.** *J Thromb Haemost.* 2010; **8**(12): 2766–2774.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Rauzi F, Smyth E, Emerson M: **Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses *In Vivo*.** *Thromb Haemost.* 2017; **117**(12): 2283–2290.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 25 May 2018

<https://doi.org/10.5256/f1000research.15737.r34024>

© 2018 Harper A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alan G.S. Harper

Institute for Science and Technology in Medicine, Keele University, Keele, UK

Mice are widely used in the platelet research field - this is largely due to this species' accessibility to genetic modification and intravital microscopy. However due to their small blood volume and size and the variable responses to surgical treatments, these experiments often require the use of significant number of mice to reproduce the experiments to get statistically significant data. Therefore there is a key need to identify 3Rs strategies to help platelet researchers minimise the harm done to mice used in this field.

In this report, the authors provide an interesting and insightful review into the 3R's approaches that have been applied to both *ex vivo* and *in vivo* studies of platelet function in mice. Taylor and Emerson provide excellent examples of how 3Rs approaches are being used and developed in their laboratory to help refine and reduce the use of mice in platelet research. Of the different approaches, the refinement of the thromboembolic model provides a particularly valuable case study into how 3Rs approaches can not only improve animal welfare but also improve the quality of the scientific data obtained.

Whilst the authors discuss barriers to the dissemination of their technique, it would have been interesting to have seen more detailed description of these barriers, and a consideration of potential ways they could be overcome to further increase the 3Rs impact of this work. For example, a more detailed assessment of the training, financial and infrastructure needs required to adopt this technique and how this lead to the development of the cell counting model, would have provided an interesting insight into how to improve the impact of 3Rs interventions.

The discussion of the uses of the thromboembolic and vascular injury models identifies some key differences between these models, however the review seems to more consider the relative merits of these two techniques as approaches to studying thrombosis generally, rather than perhaps more clearly describe their complementary roles in examining thrombosis and haemostasis - with the vascular injury models better replicating normal haemostatic reactions in the absence of a complete endothelial lining rather than true arterial thrombosis, whilst the thromboembolic model better reflects the processes of venous thromboembolism where coagulation is artificially

triggered inside the intact venous system. However the key trigger of the acute cardiovascular events mentioned by the authors in their introduction is atherosclerotic plaque rupture. The review therefore would benefit from a brief mention of animal models of plaque rupture to give a more complete picture of the field. Current murine atherosclerosis models are hampered by the lack of spontaneous plaque rupture with models using requiring a mechanical trigger to elicit the full pathological response¹, therefore future 3Rs work may also be needed on common non-mouse models in rabbits, pigs and non-human primates².

For *ex vivo* studies, the authors provide some interesting case studies on how adoption of improved technology can pave the way to reduce blood volumes required to perform these studies, and as such reduce the number of mice utilised. The authors show that these have the potential to have a major impact in reducing the number of animals. However this section does not appear to fit with the title of the review – therefore the review is brief and omits some promising 3Rs *ex vivo* approaches. The most important omission is of studies aiming to replace the use of mice in platelet research by attempting to recreate the physical and chemical environments of the circulation *ex vivo* using microfluidic and tissue engineering techniques³. These are beginning to provide a viable alternative to current animal models, and should also be considered as a potential future target of 3Rs interventions in platelet research.

Does the review provide an accurate account of the 3Rs landscape in that field / across fields?

Partly

References

1. Kuijpers MJ, Gilio K, Reitsma S, Nergiz-Unal R, et al.: Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. *J Thromb Haemost.* 2009; **7** (1): 152-61 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Emini Veseli B, Perrotta P, De Meyer GRA, Roth L, et al.: Animal models of atherosclerosis. *Eur J Pharmacol.* 2017; **816**: 3-13 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Jain A, Barrile R, van der Meer AD, Mammoto A, et al.: Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. *Clin Pharmacol Ther.* 2018; **103** (2): 332-340 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: I currently hold NC3R and British Heart Foundation funding to investigate the use of tissue-engineered human arterial constructs as an alternative to arterial thrombosis models.

Reviewer Expertise: Platelet physiology, calcium signalling, vascular tissue engineering

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 23 May 2018

<https://doi.org/10.5256/f1000research.15737.r34026>

© 2018 Grieve D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David J. Grieve

Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK

This is an interesting and important article describing development of an improved experimental model of thromboembolism with clear potential to both replace and refine existing models. Whilst the manuscript is generally well written and presented, I do think that it could be significantly improved by revising structure and increasing 3Rs emphasis. Specific comments below.

The title of the article does not accurately reflect its content. It is too general and should be specifically focussed on thromboembolism with regard to development of an improved experimental model. The stated scientific benefits in the research highlights box could also be made more specifically and understandable on a stand-alone basis.

The article would benefit from inclusion of one of two figures to complement the text and make the article more engaging. For example, a summary of current experimental models used in platelet research with approximation of numbers of animals used would be helpful and it would also seem appropriate to include a schematic representation of the new model highlighting potential benefits.

Need for animals models: the flow of this section could be improved. I do not think that the final paragraph really fits as currently written. More specific detail should also be provided in relation to the provided NC3Rs link e.g. research group etc.

With specific regard to thromboembolism models, some discussion in relation to where these procedures are currently performed (e.g. are they permitted in the UK?) and comparison of scientific end-points between the new and existing models would be informative in order to highlight relevance and applicability.

Dissemination and uptake: this section is quite weak at present and could be improved by

including discussion of e.g. current barriers to uptake and potential approaches to encourage wider implementation. At present, discussion is largely limited to the authors own collaborators and in line with NC3Rs policy more needs to be done (which I am sure that it is) to promote wide uptake of new experimental models across the field.

Abstract – specify light transmission aggregometry techniques.

Does the review provide an accurate account of the 3Rs landscape in that field / across fields?

Yes

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Referee suggested by the NC3Rs for their scientific expertise and experience in assessing 3Rs impact. Additional expertise: cardiovascular remodelling, heart failure, oxidative stress, endothelial progenitor cells, diabetes, experimental models, 3Rs.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 22 May 2018

<https://doi.org/10.5256/f1000research.15737.r34028>

© 2018 Jones S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sarah Jones

School of Healthcare Science, Manchester Metropolitan University, Manchester, UK

The availability of appropriate platelet function assays and thrombosis models is crucial to study

mechanisms, which regulate the initiation and development of platelet rich thrombi, responsible for myocardial infarction and stroke. The study of specific proteins through altering expression levels in vitro is not possible in platelets since they do not have a nucleus. The use of genetically modified mice has therefore been crucial in furthering our understanding of platelet biology over the last two decades. European and UK legislations require that all animal procedures, are given suitable consideration to the 3Rs; reduction, refinement and replacement. In this review, Taylor and Emerson highlight some of the key developments in the platelet field, promoting the 3Rs principles, and discuss recent application of these developments. Critically, the review emphasises that impact on the 3Rs, can only be achieved through uptake of alternative technologies by the scientific community, which remains a significant challenge.

The review gives a brief but comprehensive summary of recent techniques, which have had a significant impact on reducing animal numbers used in ex vivo platelet studies. These techniques allow for smaller blood volumes to yield meaningful functional data, reducing the number of animals sacrificed. Further on going research optimising flow cytometry techniques by the Emerson group, may ultimately lead to the acquisition of platelet function and signalling data, in blood samples obtained by micro-sampling. This could replace the need for blood collection methods such as cardiac puncture, which are performed under terminal anaesthesia.

A brief mention is given to the existing vascular damage models of thrombosis. The authors should be cautious in this section, to be specific with the model that they are referring to and avoid over-generalization. While it is true that arterial thrombosis, mediated by ferric chloride (FeCl_3) and measured by vascular occlusion can only assess one thrombi per animal and data is variable, this is not the case for laser injury, analysed by intravital microscopy. In this model, in excess of 20 thrombi can be analysed per animal and as few as 3 animals used in each experimental group^{1,2}.

The review highlights the importance of endothelial derived platelet inhibitors in regulating thrombosis and haemostasis, and using nitric oxide as an example, indicates that vascular injury models have yielded contradicting results. While I am in agreement with this, I do not think that the approaches in the cited studies can be referred to as similar. Differences in animal age, the mode and extent of vascular damage, and the type of vessel studied likely reflects the different results reported. Even studies using FeCl_3 to injure the carotid artery vary significantly when FeCl_3 is applied at different concentrations or for different lengths of time³.

As part of the discussion around measuring endothelial contributions to thrombosis, the authors state 'Assessment of the role of endothelial mediators requires, rather than a vascular injury approach, a model in which platelets circulate freely in the context of a functional vascular endothelium, which can be manipulated pharmacologically or genetically.' While this may be correct in a specific context, the appropriate model to investigate the role of endothelial derived mediators depends very much upon the research question. To investigate, the role of endothelial derived inhibitors on platelet aggregation in vivo, a model where platelets are circulating freely with a functional endothelium is appropriate. If however the contribution of the endothelium to arterial thrombosis or antithrombotic efficacy is being investigated, models, which encapsulate platelet adhesion, aggregation and thrombus stability in arterial conditions, following vascular damage, are more appropriate. It is also important to note that endothelial dysfunction is common in many diseases, which predispose to thrombosis, however currently there are no in vitro or in vivo models available to investigate the impact of this on thrombus generation.

The review gives an excellent summary of the thromboembolism model developed by Emerson and colleagues, with well supported statistics of the significant impact on 3Rs that it has had so far. There is also good reference to application of the model in a variety of studies. There is good critique pertaining to limited uptake of the model by the scientific community, and potential reasons for this are discussed. The Emerson group have developed a further model, which is cost-effective, requires minimal training and non-specialised equipment, to try and address some of these issues and overcome the challenge of increased uptake. In summary, this review highlights important work carried out by the Emerson group, supported by the National Centre for the Replacement, Refinement and Reduction of Animals in Research, which has successfully developed, validated and applied refined real-time thromboembolisms models to replace the severe and archaic thromboembolism model that uses mortality or hind limb paralysis as an end-point.

Does the review provide an accurate account of the 3Rs landscape in that field / across fields?

Yes

References

1. Falati S, Gross P, Merrill-Skoloff G, Furie BC, et al.: Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. *Nat Med*. 2002; **8** (10): 1175-81 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Jones CI, Tucker KL, Sasikumar P, Sage T, et al.: Integrin-linked kinase regulates the rate of platelet activation and is essential for the formation of stable thrombi. *J Thromb Haemost*. 2014; **12** (8): 1342-52 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Owens AP, Lu Y, Whinna HC, Gachet C, et al.: Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. *J Thromb Haemost*. 2011; **9** (9): 1862-3 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Platelets, endothelial cells, thrombosis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research